CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Open Access
- 1 June 2002
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 1 (5), 421-432
- https://doi.org/10.1016/s1535-6108(02)00070-3
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survivalBlood, 2002
- Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blastsLeukemia, 2001
- Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemiaBritish Journal of Haematology, 2001
- Oncogenic kinase signallingNature, 2001
- FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk groupBritish Journal of Haematology, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJCI Insight, 2000
- CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion ProteinsBlood, 1997
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells.Molecular and Cellular Biology, 1993
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990